<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00474838</url>
  </required_header>
  <id_info>
    <org_study_id>KIIT-KMC-0701</org_study_id>
    <nct_id>NCT00474838</nct_id>
  </id_info>
  <brief_title>Study To Evaluate Beta Cell Function and Glycemic Outcome by Intensive Insulin Therapy</brief_title>
  <acronym>KIIT</acronym>
  <official_title>The Effect of Intensive and Short-term Insulin Treatment on Long-term Pancreatic β-cell Function in Newly Diagnosed People With Type 2 Diabetes in Korea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyunghee University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Korea University Guro Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hanyang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Inha University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ajou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>East West Neo Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Catholic University of Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jeju National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kyunghee University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized controlled prospective study aims to evaluate the efficacy of intensive
      insulin therapy for long term glycemic control and improvement or preservation of beta cell
      function in newly diagnosed type 2 diabetes patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type 2 diabetes is associated with beta cell dysfunction and insulin action at diagnosis of
      diabetes. Although the relative importance of these two alterations is controversial, growing
      evidence is swinging to the concept that there is no hyperglycemia without β-cell
      dysfunction. Also there is agreement that deterioration of glucose tolerance over time is
      associated with a progressive decrease of beta cell function.

      Beside the role of genetic factor, the continuous decline in β-cell function is affected by
      glucotoxicity generated by hyperglycemia and lipotoxicity due to high fatty acid. A vicious
      cycle of hyperglycemia per se further impairs and may destroy β-cell. Recently, many reports
      have shown that early intensive glycemic control plays a role in the prevention of
      progressive ß-cell function and worsening of diabetes.

      Some studies have shown that early intensive insulin therapy(IIT) to achieve near
      normoglycemia in new onset type 2 diabetes gives short term and long term improvement in
      glycemic control after discontinuation of insulin. It is suggested that long term glycemic
      control is associated with improvement of β-cell function.

      In the unpublished previous pilot study, the investigators found that early intensive insulin
      therapy using multiple daily injection (MDI) or daily twice injection in newly diagnosed type
      2 diabetes can significantly improve the beta cell function and facilitate further long term
      glycemic control. To establish the effectiveness of intensive insulin therapy for long term
      glycemic control and improvement of β-cell function, the investigators will perform a
      randomized controlled prospective study in newly diagnosed type 2 diabetes in Korea.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Long-term glycemic control</measure>
    <time_frame>up to 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of pancreatic beta cell function</measure>
    <time_frame>up to 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inflammatory marker and insulin sensitivity</measure>
    <time_frame>up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach target goal of blood glucose level</measure>
    <time_frame>up to 2 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">112</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Pancreatic Beta Cell Function</condition>
  <condition>Glucotoxicity</condition>
  <arm_group>
    <arm_group_label>Oral AntiDiabetic Drug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>glimepiride and metformin and/or once daily glargine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intensive insulin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>insulin glargine insulin glulisine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intensive insulin group</intervention_name>
    <description>Once daily long acting insulin and preprandial rapid acting insulin injection</description>
    <arm_group_label>intensive insulin group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral AntiDiabetic Drug (glimepiride and metformin)</intervention_name>
    <description>glimepiride and metformin combined therapy</description>
    <arm_group_label>Oral AntiDiabetic Drug</arm_group_label>
    <other_name>glimepiride(amaryl)</other_name>
    <other_name>metformin(diabex)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed drug naïve type 2 diabetic patient with typical diabetic symptom
             (polydipsia, polyuria, unexplained weight loss) within recent 1 year

          -  Initial HbA1c : 8.0 % ≤ HbA1c &lt; 12.0%

        Exclusion Criteria:

          -  Known contraindication to insulin glargine, insulin glulisine, metformin, glimepiride

          -  Patients with proliferative diabetic retinopathy

          -  Severe liver disease or AST, ALT ≥ 2.5 x ULN

          -  History of lactic acidosis

          -  Unstable or severe angina

          -  Congestive heart failure

          -  Chronic disease treated with continuous corticosteroid therapy

          -  Diagnosis of cancer

          -  Positive urine pregnancy test or plan to become pregnant during the clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeong-taek Woo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyunghee University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hanyang University Medical Center</name>
      <address>
        <city>Kuri</city>
        <state>Kyunggi-do</state>
        <zip>471-020</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea Bucheon St.Mary's Hospital</name>
      <address>
        <city>Bucheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>In Cheon</city>
        <zip>400-711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jeju National University Hospital</name>
      <address>
        <city>Jeju-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyunghee University Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>130-702</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>152-730</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyung Hee University East Weast Neo Medicalcenter</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ajou University Medical Center</name>
      <address>
        <city>Suwon</city>
        <zip>443-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2007</study_first_submitted>
  <study_first_submitted_qc>May 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2007</study_first_posted>
  <last_update_submitted>September 25, 2013</last_update_submitted>
  <last_update_submitted_qc>September 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kyunghee University Medical Center</investigator_affiliation>
    <investigator_full_name>Jeong-taek Woo</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>type 2 diabetes mellitus</keyword>
  <keyword>intensive insulin therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Glimepiride</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Hypoglycemic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

